Moreover, studies have demonstrated the efficacy of PEG-PCL-Tat as a delivery system for siRNA to the brain via intranasal administration, with promising results in both malignant glioma [38] and cerebral ischemia-reperfusion injury rat models [34]. The gene discussed is TAT; the disease is malignant glioma.